GIO Therapeutics

On International Day of Women and Girls in Science, GIO Therapeutics recognises the contributions of women in science and biotechnology. We are proud of the women in our team leading discoveries in GPCR-targeted drug development and working together to drive progress in the field. #WomenInScience #InternationalDayOfWomenAndGirlsInScience #GIOTherapeutics #DrugDiscovery

Our CSO/COO of GIO Therapeutics Tilly (Matilda) Bingham will be attending the 2nd EFMC International Symposium on Chemical Biology from 29th - 31st January 2025 at the Congress Centre, Basel. If you’re attending, and would like to meet, please feel free to reach out! #EFMC #GIOtherapeutics #Drugdiscovery #Science #ChemicalBiology

GIO Therapeutics are excited to share that our Chair, Clare Doris, will be participating in the BioSeed Conference in London on 20th January 2025.   BioSeed is an important event where life sciences companies meet seed-stage investors. Clare will present the GIO investment opportunity. If you’re attending, don’t miss the chance to connect with Clare!   #BioSeed2025 #LifeSciences #Innovation #DrugDiscovery #Science

GIO Therapeutics would like to wish everyone a very Merry Christmas and a Happy New Year! We want to take a moment to thank everyone we’ve had the privilege of working with in 2024. We look forward to creating more success together in the coming year!

Our CSO/COO, Tilly (Matilda) Bingham, will be attending the GPCRs Targeted Drug Discovery Summit in London from 26th to 28th November 2024. GPCRs have long been recognised for their therapeutic potential, and with recent advances in technology and biology, we are now able to target them in ways that were not possible before. At GIO Therapeutics, we are focused on exploring this potential to develop treatments for cancer and inflammatory diseases. Please feel free to reach out if you'd like to connect and find out more! #GPCRSummit2024 #DrugDiscovery #Science #Networking #LondonConferences

I'm pleased to announce that our CSO/COO, Tilly (Matilda) Bingham, is attending the 36th EORTC-NCI-AACR Symposium in Barcelona from October 23-25. This event is a key gathering of leading voices in cancer research and drug development. Tilly is eager to connect with fellow experts, share our latest insights and discuss the latest advancements in oncology. If you are attending, make sure to connect with her at the event! #EORTCNCIAACR #CancerResearch #Oncology #Innovation #Barcelona2024 #GIOTherapeutics

👩🔬 We’re excited to share that our CSO/COO, Tilly (Matilda) Bingham, will be attending the 9th RSC/SCI Symposium on GPCRs in Medicinal Chemistry from October 2nd-4th. At GIO Therapeutics, we are focused on unlocking the potential of GPCRs to develop targeted treatments for oncology and inflammatory diseases. If you'd like to learn more, don’t hesitate to connect with Tilly during the event. #GPCRs2024 #Oncology #InflammatoryDiseases #GPCRResearch #GIOTherapeutics

🌟 Last week, the GIO Therapeutics team had the pleasure of visiting our amazing collaborators at leadXpro AG! Our Chief Scientific Officer, Tilly (Matilda) Bingham, and Senior Director of Scientific Affairs, Nikki March, had a fantastic time exploring lXp's 3D technology, which allowed them to dive deep into visualizing compound and receptor interactions of GPR68. A big thank you to the incredible leadXpro AG team for hosting us and continuing to be such great partners in innovation. We’re excited about what’s ahead in our collaboration! 🙌🔬 #DrugDiscovery #Collaboration #Innovation   

📣 GIO Therapeutics is attending the IFODS Conference, Paris, on 12th – 14th June 2024 and has been selected for a pitch at the Onco Startup Summit! Our Chief Executive Officer, Xavier Leroy, is eager to connect with you during the event. If you're also attending, please don't hesitate to get in touch!   #IFODSConference #Biotech #Oncology #Research #Networking